Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IL-21: Interim Phase I data

Interim data from a dose-escalation Phase I trial in 15 patients showed that IL-21 plus Rituxan rituximab

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE